Multi-specific antibodies and cell therapies enter phase 1
Assets targeting PSMA and KRAS G12V, plus another gamma-delta Car-T therapy, feature among recently disclosed first-time clinical trial entrants.
A flurry of first-in-human trial initiations
Projects from Affini-T, Bolt, Chimeric and Alentis, all hitting novel targets, as well as one from A2 using an old one, are set for first clinical trial entry.
